![Switzerland, COVID-19 response in Intensive care unit of HUG. Clean room (no covid-19) where "clean" nurses prepare medicins. April 14, 2020. Switzerland, COVID-19 response in Intensive care unit of HUG. Clean room (no covid-19) where "clean" nurses prepare medicins. April 14, 2020.](/sites/default/files/styles/full_default/public/2020-07/covid19_switzerland_intensivecareunit_2020_norateylouni_msf315071_3800px.jpg?itok=QeGHPRtn)
Achieving equitable global access resulting from the ACT Accelerator
![](/sites/default/files/styles/edition_image/public/2020-07/act_access_proposals_final_june_20_page_1.jpg?itok=Hho6LsBI)
The Access to COVID-19 Tools Accelerator (ACT-A) has the potential to galvanise governments and global health actors to operationalise the proposed equitable global access policies and practices for COVID-19 health tools: implement full transparency and guarantee public accountability from priority setting to delivery; guarantee adequate production and fair allocation with a global scope; ensure products will be affordable to healthcare payers and free to the public at the point of care in all countries; and create cooperation among initiatives to work towards the public common good.
In this briefing document, MSF, the European Alliance for Responsible R&D and Affordable Medicines, and several other civil society organisations (CSOs) set out the principles and practices that should be implemented within ACT-A to maximise equitable reach and global health impact.
Only by integrating these principles and practices putting public health interest at the core will ACT-A become a truly inclusive partnership that addresses some of the global challenges created by the COVID-19 pandemic.